Safety of House Dust Mite Synthetic Peptide Immuno-Regulatory Epitopes in Patients with House Dust Mite Allergy and Controlled Asthma

Methods Patients with House Dust Mite (HDM) allergic rhinoconjunctivitis and GINA step 1 (N=17) or GINA 2 (N=13) controlled asthma were randomised to receive 4 doses of HDM-SPIRE 12-nmol or matching placebo by intradermal injection at 4-weekly intervals.

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 135; no. 2; p. AB142
Main Authors Pawsey, Stephen, MD, Patel, Deepen, MD, Hafner, Rod, PhD, Hickey, Pascal L.C., PhD, Powell, John, MD
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Limited 01.02.2015
Subjects
Allergies
Allergy and Immunology
Asthma
Dust
Medical treatment
Online AccessGet full text

Cover

More Information
Summary:Methods Patients with House Dust Mite (HDM) allergic rhinoconjunctivitis and GINA step 1 (N=17) or GINA 2 (N=13) controlled asthma were randomised to receive 4 doses of HDM-SPIRE 12-nmol or matching placebo by intradermal injection at 4-weekly intervals.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2014.12.1400